Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
about
Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapyThe Current Status of Gene Therapy for Prostate Cancer.Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease.Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.In situ gene therapy for prostate cancer: immunomodulatory approaches.Proposed mechanisms of action for prostate cancer vaccines.Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations.Gene delivery and gene therapy of prostate cancer.Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model.Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.Chapter seven--Cancer treatment with gene therapy and radiation therapy.Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.Relative activity and specificity of promoters from prostate-expressed genes.Prostate cancer vaccines: Update on clinical development.Transcription-targeted gene therapy for androgen-independent prostate cancer.Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.The role of herpes simplex virus thymidine kinase in the treatment of solid tumours.Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene.Similar efficiency of DNA-liposome complexes and retrovirus-producing cells for HSV-tk suicide gene therapy of peritoneal carcinomatosis.Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
P2860
Q28363609-A2D99CEB-FABA-45EA-AFEE-B234B78F27FEQ33889283-0E150807-99FA-4017-8E52-C151CE78F8C3Q33947221-8A24346E-C4CB-4B54-A0B7-EAA890B71259Q34208293-72073C3C-ACA5-4197-8929-0C7F6979B30AQ34452001-400B1EDB-D1AA-4378-9CB9-D2C8AD4385B8Q35174754-0CF57234-3634-4A73-BDA2-92FF35571820Q36179778-D55E539A-E545-4B75-A0CF-9513EC539666Q36349678-DD67E6C5-49C8-4D7F-A7B2-ED53EF9F8936Q37247348-FA67EB25-005B-4EF9-97B9-0EC3A23AD045Q37436531-B1E7060F-DE38-4514-8B74-4DE446661EF8Q37861631-1BEA51FB-F1E5-4CC1-825E-91C3014FE67DQ38047477-34B96152-3DD4-43EB-A92E-117C7F0AE2CBQ39181862-8191A83B-5381-4188-90AE-DAE1D82CA9CFQ40223070-02E0B55C-1AFC-46EF-AB42-6021149E2B24Q40519641-CB8707B9-6785-400C-AD04-B2CDE587831BQ40665345-13865B26-A49B-4AC5-B70F-04C3F30AE9B3Q40704797-55D7A8DF-7397-4FBA-8A05-54173859AC7AQ40937528-8AFE73F6-C6CC-4D52-B401-0A32C15E7FE1Q41051408-CD06E2D8-32A6-4A86-A5CD-D73E6D05252DQ41220895-4465D2B3-4782-435C-9475-308B0B6E8B6AQ43169344-496EF31A-39EF-41F8-82EE-47D1C526F356Q43586560-FBC5BDAA-CED9-41A5-BFBB-2B290727DDAEQ43955932-65009A20-F32C-4150-9FD4-8BCA958EF60AQ44012459-853A78DE-8DBB-49B1-BED2-3E9E85DE2CEBQ44113154-FAD4A232-CF11-4ECC-BCC2-9C246BFC8926Q45747423-DE7CDD1D-0ED6-46CD-BA97-9AEA16421C3DQ45868617-99B9A5B9-E320-419C-B9DB-1F4E74ACC315Q45885542-EC50EE0C-6F13-42F3-84A5-3DBDCBA132FEQ52650848-06A86480-6394-4B02-98C4-B9B873BC4C58
P2860
Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Prostate cancer gene therapy: ...... human prostate cancer models.
@en
type
label
Prostate cancer gene therapy: ...... human prostate cancer models.
@en
prefLabel
Prostate cancer gene therapy: ...... human prostate cancer models.
@en
P2093
P356
P1433
P1476
Prostate cancer gene therapy: ...... human prostate cancer models.
@en
P2093
Eastham JA
Thompson TC
P304
P356
10.1089/HUM.1996.7.4-515
P577
1996-03-01T00:00:00Z